METHOD AND KIT FOR IDENTIFYING LUNG CANCER STATUS

(19)

(11)

EP 3 792 363 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 153(4) EPC

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	12.05.2021 Bulletin 2021/19

(43)	Date of publication:
	17.03.2021 Bulletin 2021/11

(21)	Application number: 18902313.8

(22)	Date of filing: 23.01.2018

(51)

International Patent Classification (IPC):

C12Q 1/68^(2018.01)

(86)	International application number:
	PCT/CN2018/073817

(87)	International publication number:
	WO 2019/144275 (01.08.2019 Gazette 2019/31)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(71)	Applicant: Excellen Medical Technology Co., Ltd.
	Science and Technology Park, Changpin District Beijing 102200 (CN)

(72)	Inventors:
	LI, Mingming Beijing 102200 (CN) LI, Shuyu Beijing 102200 (CN) CHEN, Yanli Beijing 102200 (CN) XU, Chunye Beijing 102200 (CN) PU, Jue Beijing 102200 (CN)

(74)	Representative: Glück Kritzenberger Patentanwälte PartGmbB
	Hermann-Köhl-Strasse 2a 93049 Regensburg 93049 Regensburg (DE)

(54)	METHOD AND KIT FOR IDENTIFYING LUNG CANCER STATUS

(57) Provided herein is a method for identifying lung cancer status in a subject comprising: collecting a biological sample from the subject; detecting the methylation level of a biomarker gene in the biological sample, the biomarker gene being one or more selected from the following genes: BCAT1, CDH1, DCLK1, FOXL2, HOXA9, PTGER4, RARB, RASSF1A, Septin9, and SHOX2; and comparing the detected methylation levels with a normal methylation level of a corresponding biomarker gene in the population to determine the lung cancer status in the subject. Also provided herein is a kit for identifying lung cancer status in a subject.